GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ProSomnus Inc (OTCPK:OSAPQ) » Definitions » COGS-to-Revenue

ProSomnus (ProSomnus) COGS-to-Revenue : 0.51 (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is ProSomnus COGS-to-Revenue?

ProSomnus's Cost of Goods Sold for the three months ended in Mar. 2024 was $3.83 Mil. Its Revenue for the three months ended in Mar. 2024 was $7.46 Mil.

ProSomnus's COGS to Revenue for the three months ended in Mar. 2024 was 0.51.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. ProSomnus's Gross Margin % for the three months ended in Mar. 2024 was 48.61%.

ProSomnus COGS-to-Revenue Historical Data

The historical data trend for ProSomnus's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProSomnus COGS-to-Revenue Chart

ProSomnus Annual Data
Trend Dec20 Dec21 Dec22 Dec23
COGS-to-Revenue
0.50 0.48 0.47 0.49

ProSomnus Quarterly Data
Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.47 0.46 0.51 0.53 0.51

ProSomnus COGS-to-Revenue Calculation

ProSomnus's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=13.641 / 27.652
=0.49

ProSomnus's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=3.833 / 7.458
=0.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ProSomnus  (OTCPK:OSAPQ) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

ProSomnus's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 3.833 / 7.458
=48.61 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

ProSomnus COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of ProSomnus's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

ProSomnus (ProSomnus) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ProSomnus Inc (OTCPK:OSAPQ) » Definitions » COGS-to-Revenue
Comparable Companies
VERO PBIO SIEN TLIS FZMD BTCY AIMD GTHP ODYY NMRD ABT SYK MDT BSX SZSE:300760 EW DXCM ZBH STE XAMS:PHIA
Traded in Other Exchanges
N/A
Address
5675 Gibraltar Drive, Pleasanton, CA, USA, 94588
Website
https://www.prosomnus.com
ProSomnus Inc is a medical device manufacturer. It manufacturers precision, mass-customized oral appliance therapy devices to treat obstructive sleep apnea, which affects over 74 million Americans and is associated with serious comorbidities, including heart failure, stroke, hypertension, morbid obesity and type 2 diabetes. ProSomnus's patented devices are more comfortable and less invasive alternative to continuous positive airway pressure therapy, and lead to more effective and patient-preferred outcomes.
Executives
Sung Kim officer: Chief Technical Officer 5675 GIBRALTAR AVENUE, PLEASANTON CA 94588
John Steffens 10 percent owner C/O DIGITALBRIDGE GROUP, INC., 750 PARK OF COMMERCE DRIVE SUITE 210, BOCCA RATON FL 33487
Gregory P. Ho 10 percent owner C/O SPRING MOUNTAIN CAPITAL, LP, 650 MADISON AVENUE, 20TH FLOOR, NEW YORK NY 10022
Brian B Dow officer: Chief Financial Officer 5675 GIBRALTAR AVENUE, PLEASANTON CA 94588
Smc Holdings Ii, Lp 10 percent owner 65 EAST 55TH STREET, 33RD FLOOR, NEW YORK NY 10022
Smc Holdings Ii G.p., Llc 10 percent owner C/O SPRING MOUNTAIN CAPITAL, LP, 650 MADISON AVENUE, 20TH FLOOR, NEW YORK NY 10022
Laing Rikkers director 5675 GIBRALTAR AVENUE, PLEASANTON CA 94588
Len Liptak director, officer: Chief Executive Officer 5675 GIBRALTAR AVENUE, PLEASANTON CA 94588
Mark Thomas Murphy officer: Chief Growth Officer 5675 GIBRALTAR AVENUE, PLEASANTON CA 94588
Hgp Iii, Llc 10 percent owner 3708 ASHFORD PLACE, GREENVILLE NC 27858
Steven Robert Pacelli director 5555 OBERLIN DRIVE, SAN DIEGO CA 92121
Hmc, Llc 10 percent owner 3708 ASHFORD PLACE, GREENVILLE NC 27858
Healthpointcapital, Llc 10 percent owner C/O HEALTHPOINTCAPITAL, 505 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Healthpointcapital Partners Iii Lp 10 percent owner 505 Park Avenue, 12th Floor, New York NY 10022
Leonard Hedge director 7855 BELLA MONTANIA LANE, PALO CEDRO CA 96073